The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two ...
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its ...
At a contentious meeting with possible implications for other rare disease drugmakers, outside experts ultimately determined ...
Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher ...
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public ...
Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall ...
Vertex Pharmaceuticals has struck a deal with AbCellera to develop new types of T-cell engagers for autoimmune diseases and, ...
Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy ...
The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss ...
High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with ...
Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results